Endocrine, metabolic, and clinical effects of gestrinone in women with endometriosis
- 1 October 1989
- journal article
- research article
- Published by Elsevier in Fertility and Sterility
- Vol. 52 (4) , 589-595
- https://doi.org/10.1016/s0015-0282(16)60969-x
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosisAmerican Journal of Obstetrics and Gynecology, 1988
- Impact of gestrinone on the course of asymptomatic endometriosis.BMJ, 1987
- Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesteroneAmerican Journal of Obstetrics and Gynecology, 1986
- Clinical Management of Endometriosis with Luteinizing Hormone - Releasing Hormone AnaloguesSeminars in Reproductive Medicine, 1985
- Effect of gestrinone in endometriosis tissue and endometriumFertility and Sterility, 1985
- Revised American Fertility Society Classification of Endometriosis: 1985Fertility and Sterility, 1985
- Treatment of endometriosis with danazol: report of a 6-year prospective studyFertility and Sterility, 1985
- Danazol: Endocrine consequences in healthy women***American Journal of Obstetrics and Gynecology, 1981
- Danazol Binding to Rat Androgen, Glucocorticoid, Progesterone, and Estrogen Receptors: Correlation With Biologic ActivityFertility and Sterility, 1979
- Episodic Luteinizing Hormone Secretion in Man PULSE ANALYSIS, CLINICAL INTERPRETATION, PHYSIOLOGIC MECHANISMSJournal of Clinical Investigation, 1973